Life Science ecosystem in Milan: meeting with Swiss delegation
The Centre for Innovation and Technology Transfer (CITT) at Human Technopole and the Swiss diplomatic representation in Italy, in collaboration with YES MILANO, organised a day-long meeting between Swiss and Italian players working in the field of life sciences. The initiative followed a study tour that CITT experienced in Switzerland in June 2022 to get to know partners in the Swiss innovation ecosystem and pave the way for future collaborations and sharing of best practices on the topic of technology transfer.
The meeting, hosted at the Human Technopole headquarters within MIND – Milano Innovation District, allowed the various entities involved to initiate new relationships and strengthen existing ones.
The programme for the day included a presentation of the Milan life sciences ecosystem, coordinated by Piergiorgio Borgogelli of YES MILANO and involving: Margherita Chierici (TTO IRCCS Ca’ Granda Ospedale Maggiore Policlinico), Daniela Bellomo (Business Development Director San Raffaele), Stefano Minini (Director Lendlease), Felice Lopane (Life Sciences Assolombarda Coordinator), Francesco Cerruti (General Manager Italian Tech Alliance), Paola Testori Coggi (Ambassador Federated Innovation MIND). In the second part of the programme, the Swiss delegation had the opportunity to introduce themselves to the Italian delegates in a pitching session followed by bilateral meetings.
Attached is a copy of the program.
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.